Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Anflu Vaccine
NCT00556062Phase 4Completed
- Sponsor
- Sinovac Biotech Ltd.
- Start
- Sep 2007
- Modality
- Vaccines & Immunotherapeutics
01
Overview
Phase 4, randomised, double-blind trial of influenza vaccine in influenza (4 arms), sponsored by Sinovac Biotech Ltd. Primary endpoint: Haemagglutination-inhibition antibody titer at 21 days. Started Sep 2007; status: completed.
02
Drugs
influenza vaccine
03
Conditions
influenza
Beyond the preview
Go deeper on NCT00556062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00556062.